- Home
- SEPN vs ATYR Comparison
SEPN vs ATYR Comparison
Compare SEPN & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEPN
- ATYR
- Stock Information
- Founded
- SEPN 2022
- ATYR 2005
- Country
- SEPN United States
- ATYR United States
- Employees
- SEPN N/A
- ATYR N/A
- Industry
- SEPN
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEPN
- ATYR Health Care
- Exchange
- SEPN NYSE
- ATYR Nasdaq
- Market Cap
- SEPN 453.2M
- ATYR 451.3M
- IPO Year
- SEPN 2024
- ATYR 2015
- Fundamental
- Price
- SEPN $11.76
- ATYR $5.30
- Analyst Decision
- SEPN Strong Buy
- ATYR Strong Buy
- Analyst Count
- SEPN 5
- ATYR 6
- Target Price
- SEPN $26.75
- ATYR $20.20
- AVG Volume (30 Days)
- SEPN 443.6K
- ATYR 3.7M
- Earning Date
- SEPN 08-15-2025
- ATYR 08-12-2025
- Dividend Yield
- SEPN N/A
- ATYR N/A
- EPS Growth
- SEPN N/A
- ATYR N/A
- EPS
- SEPN N/A
- ATYR N/A
- Revenue
- SEPN $977,000.00
- ATYR N/A
- Revenue This Year
- SEPN N/A
- ATYR $960.85
- Revenue Next Year
- SEPN $526.96
- ATYR $1,283.47
- P/E Ratio
- SEPN N/A
- ATYR N/A
- Revenue Growth
- SEPN 108.76
- ATYR N/A
- 52 Week Low
- SEPN $4.17
- ATYR $1.58
- 52 Week High
- SEPN $28.99
- ATYR $5.98
- Technical
- Relative Strength Index (RSI)
- SEPN N/A
- ATYR 56.28
- Support Level
- SEPN N/A
- ATYR $5.07
- Resistance Level
- SEPN N/A
- ATYR $5.58
- Average True Range (ATR)
- SEPN 0.00
- ATYR 0.39
- MACD
- SEPN 0.00
- ATYR -0.04
- Stochastic Oscillator
- SEPN 0.00
- ATYR 64.20
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.